Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
Gasperetti et al., EP Europace, doi:10.1093/europace/euaa216
Gasperetti et al., Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings, EP Europace, doi:10.1093/europace/euaa216
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.
Arrhythmic safety data from a large cohort of patients treated with HCQ alone or in combination with other QT-prolonging drugs.
Gasperetti et al., 24 Sep 2020, peer-reviewed, 23 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Europace (2020) 22, 1855–1863 doi:10.1093/europace/euaa216 CLINICAL RESEARCH Arrhythmias and COVID-19 Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings 1 Heart Rhythm Center, Centro Cardiologico Monzino, IRCCS, Milan, Italy; 2University Heart Center, University Hospital Zürich, Zürich, Switzerland; 3Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy; 4Department of Cardiology, ASST-Fatebenefratelli Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy; 5Department of Cardiovascular Disease, Policlinico Umberto I Hospital, Rome, Italy; 6III Division of Infectious Diseases, ASSTFatebenefratelli Sacco, Department of Biomedical and Clinical Sciences, University of Milan, Italy; 7Division of Cardiology, Spedali Civili Hospital, Brescia, Italy; 8Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Göttingen, Germany; 9Department of Systems Medicine, University of Rome ‘Tor Vergata’, Rome, Italy; 10Department of Internal Medicine, Luigi Sacco Hospital, University of Milan, Milan, Italy; 11 Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, University of Bologna, Bologna, Italy; and 12 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy Received 6 May 2020; editorial decision 2 July 2020; accepted after revision 3 July 2020; online publish-ahead-of-print 24 September 2020 Aims The aim of the study was to describe ECG modifications and arrhythmic events in COVID-19 patients undergoing hydroxychloroquine (HCQ) therapy in different clinical settings. ................................................................................................................................................................................................... Methods COVID-19 patients at seven institutions receiving HCQ therapy from whom a baseline and at least one ECG at and results 48þ h were available were enrolled in the study. QT/QTc prolongation, QT-associated and QT-independent arrhythmic events, arrhythmic mortality, and overall mortality during HCQ therapy were assessed. A total of 649 COVID-19 patients (61.9 ± 18.7 years, 46.1% males) were enrolled. HCQ therapy was administrated as a home therapy regimen in 126 (19.4%) patients, and as an in-hospital-treatment to 495 (76.3%) hospitalized and 28 (4.3%) intensive care unit (ICU) patients. At 36–72 and at 96þ h after the first HCQ dose, 358 and 404 ECGs were obtained, respectively. A significant QT/QTc interval prolongation was observed (P < 0.001), but the magnitude of the increase was modest [þ13 (9–16) ms]. Baseline QT/QTc length and presence of fever (P = 0.001) at admission represented the most important determinants of QT/QTc prolongation. No arrhythmic-related deaths were reported. The overall major ventricular arrhythmia rate was low (1.1%), with all events found not to be related to QT or HCQ therapy at a centralized event evaluation. No differences in QT/QTc prolongation and QT-related arrhythmias were observed across different clinical settings, with non-QT-related arrhythmias being more common in the intensive care setting. ................................................................................................................................................................................................... Conclusion HCQ..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit